Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

[1]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Y. Takeda,et al.  [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer]. , 2015, Gan to kagaku ryoho. Cancer & chemotherapy.

[3]  M. Hidalgo,et al.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies , 2015, Nature Reviews Clinical Oncology.

[4]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[5]  J. Furuse,et al.  Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer , 2014, Cancer science.

[6]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[7]  H. Ueno,et al.  Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Reis,et al.  A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer , 2013, American journal of clinical oncology.

[9]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[10]  A. Tsao.  Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial , 2012 .

[11]  M. Yunokawa,et al.  Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer , 2012, Cancer Chemotherapy and Pharmacology.

[12]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Furuse,et al.  Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer , 2011, Cancer science.

[14]  J. Furuse,et al.  A late phase II study of S-1 for metastatic pancreatic cancer , 2008, Cancer Chemotherapy and Pharmacology.

[15]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Osamu Ishikawa,et al.  A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer , 2007, Cancer Chemotherapy and Pharmacology.

[17]  L. Seymour,et al.  A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. , 2006, Gynecologic oncology.

[18]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Rochat.  Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance , 2005, Clinical pharmacokinetics.

[21]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Tamburini,et al.  Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. , 1996, European journal of cancer.

[23]  J. Laliberté,et al.  Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. , 1993, Biochemical pharmacology.